These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33025535)

  • 1. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.
    Cazzola M; Page C; Rogliani P; Calzetta L; Matera MG
    Drugs; 2020 Nov; 80(17):1799-1809. PubMed ID: 33025535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdosteine: its relevance in COPD treatment.
    Moretti M
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mucolytics in COPD: A Delphi consensus study.
    Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
    Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
    Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
    Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
    Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
    Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
    Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erdosteine for COPD exacerbations.
    Drug Ther Bull; 2008 Oct; 46(10):79-80. PubMed ID: 18832259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of erdosteine antioxidant activity in experimental research.
    Moretti M; Marchioni CF
    Pharmacol Res; 2007 Apr; 55(4):249-54. PubMed ID: 17267240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis.
    Cazzola M; Calzetta L; Page C; Rogliani P; Matera MG
    Pulm Pharmacol Ther; 2018 Feb; 48():185-194. PubMed ID: 29233650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdosteine: antitussive and anti-inflammatory effects.
    Dal Negro RW
    Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
    Dal Negro RW; Visconti M
    Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
    Cazzola M; Floriani I; Page CP
    Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
    Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
    Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
    Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD.
    Dal Negro RW; Visconti M; Micheletto C; Tognella S
    Pulm Pharmacol Ther; 2008; 21(2):304-8. PubMed ID: 17889580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
    Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
    J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
    Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
    Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erdosteine.
    Dechant KL; Noble S
    Drugs; 1996 Dec; 52(6):875-81; discussion 882. PubMed ID: 8957158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.